click below
click below
Normal Size Small Size show me how
Endocrine 1
| Generic Name | Brand Name | Classification | Pharmacologic Category | Common Indications | Essential Knowledge |
|---|---|---|---|---|---|
| metformin (PO) | Fortamet, Glumetza | Biguanide | Type 2 DM, PCOS | Key Side Effects: diarrhea, nausea, vomiting, Vitamin B12 deficiency Other Notes: CI with eGFR <30 US Boxed Warnings: lactic acidosis | |
| sitagliptin (PO) | Januvia, Zituvio | Dipeptidyl peptidase (DPP-4) inhibitor | Type 2 DM | Key Side Effects: nasopharyngitis | |
| empagliflozin (PO) | Jardiance | Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | Type 2 DM, HF, CKD | Key Side Effects: genital mycotic infections, UTI | |
| dapagliflozin (PO) | Farxiga | Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | Type 2 DM, HF, CKD | Key Side Effects: genital mycotic infections, UTI | |
| glimepiride (PO) | Amaryl | Sulfonylurea | Type 2 DM | Key Side Effects: hypoglycemia, weight gain | |
| glipizide (PO) | Glucotrol, Glucotrol XL | Sulfonylurea | Type 2 DM | Key Side Effects: hypoglycemia, weight gain | |
| pioglitazone (PO) | Actos | Thiazolidinedione (TZD) | Type 2 DM | Key Side Effects: peripheral edema, weight gain, upper respiratory tract infection; increased risk of fractures and bladder cancer US Boxed Warnings: may exacerbate congestive heart failure and CI in NYHA Class III and IV | |
| dulaglutide (SQ) | Trulicity | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM | Key Side Effects: nausea, vomiting, diarrhea, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor | |
| liraglutide (SQ) | Victoza, Saxenda | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer | |
| semaglutide (PO, SQ) | SQ: Ozempic, Wegovy PO: Rybelsus | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer | |
| tirzepatide (SQ) | Mounjaro, Zepbound | Dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, increased heart rate, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor | |
| insulin glargine (SQ) | Lantus, Toujeo, Basaglar | Insulin, long acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | |
| insulin NPH (SQ) | Humulin N, Novolin N | OTC | Insulin, intermediate acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| insulin aspart (SQ) | Novolog | Insulin, rapid acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | |
| insulin lispro (SQ) | Humalog | Insulin, rapid acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | |
| insulin regular (SQ, IV) | Humulin R, Novolin R | SQ: OTC | Insulin, short-acting | Type 1 DM, type 2 DM, DKA | Key Side Effects: hypoglycemia, weight gain |